RevOpsis Therapeutics has entered a strategic manufacturing collaboration with contract development and manufacturing organisation Kemwell Biopharma to accelerate the development of new multispecific biologics.
SAN CARLOS, Calif. and BANGALORE, India, June 17, 2024 /PRNewswire/ -- RevOpsis Therapeutics, a next-generation biopharmaceutical company spearheading innovation of multispecific ophthalmic therapies, and Kemwell Biopharma, a leading biologics contract development and manufacturing organization (CDMO), announced today a broad strategic manufacturing partnership. This collaboration aims to accelerate the development of RevOpsis' lead candidate, RO-104, a first-in-class tri-specific biologic for the treatment of neovascular age-related macular degeneration (nAMD).
WARREN, N.J., Jan. 8, 2024 /PRNewswire/ -- Cipla (EU) Limited, UK a wholly owned subsidiary of Cipla Limited (BSE:500087; NSE: Cipla EQ], hereinafter referred to as Cipla has announced a strategic collaboration with Kemwell Biopharma Private Limited (through its subsidiary Kemwell Biopharma UK Limited) and Manipal Education & Medical Group (through its subsidiary MNI Ventures, Mauritius) to incorporate a joint venture in the United States. The primary goal of this joint venture is to develop and commercialise novel Cell therapy products for major unmet medical needs in the United States, Japan, and EU regions.
Cipla, a global pharmaceutical company, and Kemwell Biopharma, a biopharmaceutical contract development and manufacturing organization (CDMO), have entered a joint venture agreement to develop, manufacture and commercialize biosimilars for global markets. A joint venture company will be incorporated with an aim to enter the respiratory biosimilars space.
Pharma major Cipla NSE -0.55 % Limited and Bengaluru based biopharmaceutical Contract Development and Manufacturing Organisation (CDMO) Kemwell Biopharma Private Limited, entered into a joint venture agreement to develop, manufacture and commercialise biosimilars for global markets.
Kemwell Biopharma, a biologics contract development and manufacturing service provider has recently augmented its existing infrastructure. As part of this expansion strategy, the company has installed Ambr 250, a high throughput equipment with 12 fully automated mini bioreactors at a 250 ml scale to accelerate process development.
Kemwell Biopharma, a biologics contract development and manufacturing service provider, announced today that it has signed a contract to manufacture and supply drug substance using its state-of-the-art mammalian cell culture plant in India for Phase 3 clinical trials that will be conducted in the US by its customer for a BLA filing.
Swedish CDMO Recipharm’s growing global footprint in 2016 has positioned the company to take advantage of what is expected to be more consolidation and growth in the CDMO market.
Granules got the facilities in Vizag in a 2014 acquisition of Auctus Pharma for a reported $16.5 million. At the time of the deal Granules said acquiring the FDA-approved API operations would help it meet its expansion goals. The company now has 8 manufacturing sites around the world, including operations in Virginia.
Recipharm on April 18, 2016 announced that it had entered into two separate agreements to acquire pharmaceutical contract development and manufacturing operations (CDMO) from Kemwell. The first acquisition comprises operations in the US and Sweden, and the second acquisition comprises operations in India.